Axtria Challenges Life Sciences Industry to Fix AI Foundations Before Scaling
Event summary
- Axtria Ignite 2026 gathered 450+ life sciences executives in Princeton, NJ on June 10-11.
- CEO Jaswinder Chadha emphasized fixing AI foundations before scaling, citing 89% of AI pilots never reaching production.
- Ignite Leadership Awards honored transformation leaders from Bristol Myers Squibb, GSK, and Biogen.
- Quest Diagnostics received Axtria Bedrock Honor for a 15-year partnership and complex sales force alignment solution.
The big picture
Axtria's conference highlights a growing tension in life sciences: the rush to deploy AI agents (projected at 100,000+) clashes with persistent data issues (73% of biopharma) and low trust metrics. The strategic anomaly is that companies racing to scale agentic AI may be overlooking foundational requirements for long-term success. This comes as pharma accuracy standards remain at 99.5%, demanding rigorous governance frameworks for digital workers.
What we're watching
- Foundation First
- Whether life sciences companies will prioritize fixing AI foundations over rapid scaling of agentic AI.
- Trust Metrics
- The pace at which trust in AI systems recovers from 53% to meet pharma's 99.5% accuracy bar.
- Change Management
- How effectively companies integrate change management as core work rather than an afterthought.